Description of the cutaneous manifestations of Covid-19 (COVID-PIEL)

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Medical condition to be studied:
  Rash erythematous

Population studied

• Age groups:
  • Preterm newborn infants (0 – 27 days)
  • Term newborn infants (0 – 27 days)
  • Infants and toddlers (28 days – 23 months)
  • Children (2 to < 12 years)
  • Adolescents (12 to < 18 years)
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Special population of interest:
  Hepatic impaired

  Immunocompromised

  Pregnant women

  Renal impaired
• Estimated number of subjects:
  60

Study design details

• Main study objective:
  To describe the clinical characteristics and symptoms of the cutaneous manifestations associated with COVID-19.
• Outcomes:
  o Identify the chronology of the cutaneous manifestations associated with COVID-19.o Evaluate the eventual relationship of skin manifestations with current COVID-19 treatments.o Evaluate the relationship of cutaneous manifestations associated with analytical parameters
• Data analysis plan:
  The statistical analysis includes descriptive statistics using absolute frequencies and percentages. The chi-square test and odds ratio calculation will be used to test the association between skin manifestations, COVID-19 treatments and analytical parameters indicating severity.